Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535286 · ClinicalTrials.gov registry record · Phase 1
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
A Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT02535286 is a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome that has completed, run by TG Therapeutics. The registered enrollment target is 27 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02535286, a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Conditions Studied
Interventions
- DRUG Umbralisib
- BIOLOGICAL ublituximab
- BIOLOGICAL TG-1501
Study Locations (4)
New York
- TG Therapeutics Investigational Trial Site - New York
North Carolina
- TG Therapeutics Investigational Trial Site - Durham
Pennsylvania
- TG Therapeutics Investigational Trial Site - Philadelphia
Washington
- TG Therapeutics Investigational Trial Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-09-18 |
| Est. Completion | 2021-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02535286
The ClinicalTrials.gov registry entry for NCT02535286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Umbralisib is the first listed.
NCT02535286 reports 4 study locations spanning 4 distinct geographic areas - top geographies include New York, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02535286 about?
NCT02535286 is a clinical study titled "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation". The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
What is the current status of trial NCT02535286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-09-18. Estimated completion is 2021-11-04.
What conditions does trial NCT02535286 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Richter Syndrome.
What interventions are being tested in trial NCT02535286?
The interventions under investigation include: Umbralisib (DRUG), ublituximab (BIOLOGICAL), TG-1501 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02535286?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02535286 being conducted?
This trial has 4 study locations across New York, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.